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Abstract 
Background: Gender and age at onset are important epidemiological factors influencing prevalence, 
clinical presentation, and treatment response in autoimmune diseases. 
Objective: To evaluate the impact of female sex and fertile age on aquaporin-4-antibody (AQP4-ab) 
status, attack localization, and response to attack treatment in patients with neuromyelitis optica (NMO) 
and its spectrum disorders (neuromyelitis optica spectrum disorder (NMOSD)). 
Methods: Female-to-male ratios, diagnosis at last visit (NMO vs NMOSD), attack localization, attack 
treatment, and outcome were compared according to sex and age at disease or attack onset. 
Results: A total of 186 NMO/SD patients (82% female) were included. In AQP4-ab-positive patients, 
female predominance was most pronounced during fertile age (female-to-male ratio 23:1). Female 
patients were more likely to be positive for AQP4-abs (92% vs 55%; p < 0.001). Interval between onset 
and diagnosis of NMO/SD was longer in women than in men (mean 54 vs 27 months; p = 0.023). In 
women, attacks occurring ⩽40 years of age were more likely to show complete remission (p =0.003) and 
better response to high-dose intravenous steroids (p = 0.005) compared to woman at >40 years. 
Conclusion: Our data suggest an influence of sex and age on susceptibility to AQP4-ab-positive NMO/ 
SD. Genetic and hormonal factors might contribute to pathophysiology of NMO/SD. 
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Introduction Sex may also influence clinical features, disease 
Neuromyelitis optica (NMO) and its spectrum disor- course, and severity in NMO/SD. Previous studies 
ders (neuromyelitis optica spectrum disorder showed a female predominance in AQP4-ab­
(NMOSD)) are autoimmune disorders of the central seropositive patients.4,5 Male NMO patients were 
nervous system, diagnostically characterized and more likely to follow a monophasic disease course in 
pathophysiologically linked with the presence of anti- a predominantly Caucasian cohort.6 
aquaporin-4-antibodies (AQP4-abs) in the majority of 
patients.1 The female-to-male ratio markedly exceeds Over the lifespan, women undergo tremendous hor­
3:12,3 and reaches 8–9:1 in some AQP4-ab-positive monal changes, especially during puberty, pregnancy, 
populations.4 With clear female predominance in and menopause. These hormonal changes might influ­
most studies, sex emerges as one of the most impor- ence susceptibility, course, and severity of autoim­
tant factors of susceptibility to NMO/SD. mune diseases. Other autoimmune disorders, for 
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example, systemic lupus erythematosus (SLE)7 or 
multiple sclerosis (MS)8 show a clear female predom­
inance. In SLE, female-to-male ratio is most pro­
nounced during fertile age.7 In MS, male patients are 
older, more likely to develop myelopathy, and suffer 
from faster progression than female patients.9 
Increase in knowledge on sex- and age-specific 
aspects might be helpful for prognostic assessment 
and open insights in the susceptibility and pathophys­
iology of NMO/SD. 
In this study, we investigated for the first time if there 
are (1) differences in the female-to-male ratio between 
age groups in NMO/SD and (2) differences in symp­
toms of attacks and treatment response in female 
patients during and beyond reproductive age. 
Methods 
Patients were identified using the registry of the 
German Neuromyelitis Optica Study Group (NEMOS, 
www.nemos-net.de), a nationwide open association 
of neurological centers interested mainly in adult 
NMO/SD (34 German university and academic teach­
ing hospitals). Pediatric centers were not participating 
in the current study. The study was approved by the 
institutional review boards of the participating aca­
demic centers and conducted in accordance with the 
German data protection law. Between January 2012 
and March 2013, we retrospectively analysed data of 
215 NMO/SD patients which were collected cross-
sectionally in a standardized manner by two neurolo­
gists visiting the contributing centers in a “flying 
doctor” approach. 
Inclusion criterion was a diagnosis of NMO accord­
ing to Wingerchuk et al.’s criteria10 (“NMO”) or of 
isolated or recurrent AQP4-ab-positive optic neuritis 
(ON) or myelitis (“NMOSD”).11 Some patients of our 
cohort were initially misdiagnosed as MS. To avoid 
misclassification, the diagnosis at the most recent 
visit prior to data collection was used for patient strat­
ification. Demographic characteristics, diagnoses, 
duration of clinical observation, clinical attacks, 
attack treatment, and attack outcome were analysed in 
a stratified fashion according to sex and to fertile age 
in women. 
The vast majority of girls experience menarche 
around the age of 15 years, and only a very small pro­
portion of births occurs before the 15th or after the 
40th year of age.12 Moreover, menopause is very 
unlikely to occur before the age of 40 years; the risk of 
natural menopause before age 40 is approximately 
1%.13 Therefore, we defined fertile age between 15 
and 40years. Time to diagnosis, AQP4-ab status, dis­
ease classification, and the annualized relapse rate 
(ARR) were analysed according to age at disease 
onset. Attack-related factors like clinical presentation 
and attack remission were at first analysed according 
to age at attack onset. Attack treatment was escalated 
up to four times. Only first treatment courses for 
attacks were included in the analysis of treatment 
responses. 
Of 215 patients recorded in the database, 29 patients 
were excluded due to missing data or because they 
did not meet inclusion criteria. Finally, data from 
186 patients were available for statistical analysis 
(Figure 1). These patients had a total of 1124 attacks, 
but in 253 attacks, documentation on treatment and/ 
or outcome was insufficient. Therefore, only 871 
attacks were included in the final analysis. 
Demographic data, attack characteristics, therapies, 
and the short-term remission status of the complete 
cohort were previously described.14 
The statistical analysis was conducted in two steps. 
First, we analysed patient-related data such as age at 
onset, time between onset and diagnosis, AQP4-ab 
serostatus, disease classification, and ARR. Those 
analyses were accomplished using the exact chi-
square test or the exact Mann–Whitney test, accord­
ingly. Second, in order to adjust for intraindividual 
correlations within patients, we applied generalized 
estimating equations (GEEs)15 with patient as statisti­
cal unit for attack localization (type of attack) and 
attack remission. In GEE, odds ratios for risk factors 
and corresponding 95% confidence intervals (95% 
CIs) were given. Statistical analyses were performed 
using IBM© SPSS© Statistics, Version 23, 
©Copyright 1989, 2010 SPSS Inc., an IBM Company. 
Results are shown as median and interquartile range 
(IQR) or mean±standard deviation (SD) when nor­
mal distribution wasn’t rejected. Statistical signifi­
cance was set at a two-sided p <0.05. Our study was 
an exploratory analysis; therefore, no correction for 
multiple comparisons was performed. 
Results 
Female-to-male ratio in different age groups 
We identified a total of 186 patients (Figure 1). Age at 
disease onset ranged between 15 and 65 years in more 
than 90% of the patients. The youngest patient was 
8 years old at disease onset, whereas the oldest devel­
oped first symptoms at an age of 79 years (Table 1). In 
http://msj.sagepub.com 2 
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Figure 1. Flow chart of the patients enrolled in the study. 
Table 1. Demographic characteristics. 
n (%) 
Sex Female 152/186 (82) 
Male 34/186 (18) 
Age at onset <15 years 6/186 (3) 
(complete cohort, 15–40 years 89/186 (48) 
range: 8–79) 41–65 years 83/186 (45) 
>65 years 8/186 (4) 
Age at onset <15 years 4/152 (3) 
(women only) 15–40 years 78/152 (51) 
41–65 years 65/152 (43) 
>65 years 5/152 (3) 
Age at onset <15 years 2/34 (6) 
(men only) 15–40 years 10/34 (29) 
41–65 years 19/34 (56) 
>65 years 3/34 (9) 
all, 152 (82%) were female. Female-to-male ratio was 
4.5:1 in the total cohort, 8:1 in patients with disease 
onset in the fertile age, and 3:1 in patients older than 
40years at disease onset (Figure 2). In the small sub­
group of patients <15 years at onset (n =6), female-to­
male ratio was 2:1. In 183/186 patients (98%), 
information about AQP4-ab-status were available. 
Out of these, 156 (85%) were AQP4-ab-positive. In 
AQP4-ab-positive patients, female-to-male ratios 
were 3:1, 23:1, and 5:1 for age groups <15, 15–40, 
and >40years, respectively. In contrast, in AQP4-ab­
negative patients (n =27, 15%), the female-to-male 
ratios were 1:1.2 for age groups 15–40 and >40 years, 
respectively. As in AQP4-ab-negative patients only 
one patient was younger than 15 years at onset, a 
female-to-male ratio was not applicable. 
Comparison between female and male patients 
Mean duration of clinical observation in female and 
male patients was 47 (23–107) versus 68 (39– 
117)months (p = 0.054). Women tended to be younger 
(mean 39±14years) than men (mean 44±17years, 
p = 0.075) at disease onset. The majority of both men 
and women showed a relapsing disease course (91% 
and 94%, respectively), while in the remaining 
patients, a monophasic disease course was recorded. 
In women, the duration until the diagnosis of NMO/ 
SD had been confirmed was longer than in men 
(p =0.023). AQP4-abs were more frequently detected 
in female than in male patients (p <0.001; Table 2). 
The number of female and male patients receiving dis­
ease-modifying treatments (DMTs) is shown in Table 
2. The median number of DMT per patient was 2 (range 
1–8). Mean DMT interval was 441 (±421)days. 
A total of 28% of all attacks presented as ON and 59% 
as myelitis. The remaining attacks showed either 
simultaneous ON and myelitis or symptoms different 
from ON or myelitis. No differences in the frequen­
cies of ON and myelitis attacks were found between 
male and female patients (Table 2). 
In almost all patients (181/186, 97%), at least once an 
acute attack was treated with high-dose intravenous 
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Figure 2. Age distribution of female-to-male ratio. 
steroids (HD-S) as first-line treatment. A total of 27 
patients (15%) received therapeutic plasma exchange 
(TPE) and 7 (4%) received immunoadsorption as first 
treatment course of at least one attack. Frequencies of 
applied first-line therapies did not differ between men 
and women. No differences in attack localization and 
in attack outcome for any of the applied first treat­
ment courses were found between male and female 
patients (Table 2). 
Comparison between women of fertile age and 
women beyond fertile age 
Female patients younger than 15 years (n = 4) were 
not included in the analysis. To ensure a similar clin­
ical observation period in both groups, female 
patients with an observation period of <2 and 
⩾10 years (n = 55) were excluded from the analysis. 
Among the remaining 93 women, 42 were between 
15 and 40 years old at disease onset (median clinical 
observation 74 (40–88) months). A total of 51 female 
patients were older than 40 years (median clinical 
observation 51 (40–72) months; p = 0.08) at disease 
onset. A total of 468 attacks were recorded in these 
patients. 
Women ⩽40 years at disease onset were more likely 
to fulfill Wingerchuk’s criteria compared to women 
>40 years (p =0.008). No differences were detected in 
AQP4-ab status, ARR, and time between initial mani­
festation and diagnosis (Table 3). 
We found no differences in the use of first-line attack 
therapy between women ⩽40 years at disease onset 
and female patients >40years. 
Attacks in women occurring at an age of 40years or 
lower showed a higher frequency of complete attack 
remission (p =0.003) and a better response to HD-S 
(p = 0.005). The comparison of response to TPE 
between attacks occurring at an age of ⩽ and >40years 
missed significance. No differences in attack localiza­
tion were detected (Table 3). 
In order to differentiate between age and sex effects, 
we also explored the male patients. Male patients 
between 15 and 40 years at disease onset (n = 10) did 
not differ from male patients >40years (n =22) with 
regard to ARR and disease classification (NMO vs 
NMOSD). No differences in attack localization, 
attack outcome, or treatment response to HD-S and 
TPE were detected in attacks occurring at an age of 
40years or lower compared to attacks occurring at an 
age of >40years (Table 4). 
Discussion 
In our cohort of predominantly Caucasian NMO/SD 
patients, we found a significant female preponder­
ance. A total of 82% of our patients were female, 
which is in line with the results of other NMO 
cohorts.3 The female-to-male ratio at disease onset 
was most pronounced in the reproductive age between 
15 and 40 years (8:1 vs 2:1 and 3:1, respectively). 
http://msj.sagepub.com 4 
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Table 2. Comparison between female (n = 152) and male (n =34) NMO/SD patients. 
Female (n = 152) 
(reference) 
Male (n = 34) p-value Odds ratio (95% CI) 
Age at onset (years (±SD)) 39 (±14) 44 (±17) 0.08a 
Time between onset and 
diagnosis (months) 
54 (±80) 27 (±42) 0.02a 
AQP4-ab-positive 138 (92%) 18 (55%) <0.001b 
Annualized relapse rate 
(clinical observation >1 year) 
0.9 (0.6–1.4) 0.9 (0.6–1.4) 0.90a 
Disease classification 
NMOc 114/152 (75%) 29/34 (85%) 0.20b 
NMOSD 38/152 (25%) 5/34 (15%) 
Disease-modifying treatments (patients receiving treatment n) 
Rituximab 62 12 
Azathioprine 50 4 
Mitoxantrone 29 9 
Interferon-beta 26 5 
Glatiramer acetate 17 1 
Cyclophosphamide 16 0 
Steroids per os 14 2 
Steroids intrathecal 7 2 
Othersd 29 8 
Type of attack (n = 871 attacks in 185 patients) 
Optic neuritis (ON) 213/731 (29) 35/140 (25) 0.69e 1.049 (0.825–1.34) 
Myelitis 425/731 (58) 92/140 (66) 
ON + myelitis 77/731(11) 12/140 (8) 
Other 16/731 (2) 1/140 (1) 
Remission overall (n = 871 attacks in 185 patients) 
Complete 147/731 (20) 26/140 (19) 0.69e 0.888 (0.496–1.59) 
Incomplete/no 573/731 (78) 112/140 (80) 
MD 11/731 (2) 2/140 (1) 
Remission HD-S (first pulse) (n = 693 attacks in 181 patients) 
Complete 96/575 (17) 22/118 (19) 0.76e 1.102 (0.591–2.06) 
Incomplete/no 471/575 (82) 94/118 (80) 
MD 8/575 (1) 2/118 (1) 
Remission TPE (first cycle) (n = 63 attacks in 28 patients) 
Complete 18/55 (33) 1/8 (13) 0.76e 0.704 (0.075–6.57) 
Incomplete/no 36/55 (65) 7/8 (87) 
MD 1/55 (2) 0/8 (0) 
Remission immunoadsorption (first cycle) (n = 9 attacks in seven patients) 
Complete 0/8 (0) 1/1 (100) NA 
Incomplete/no 8/8 (100) 0/1 (0) 
HD-S: high-dose intravenous steroids; TPE: therapeutic plasma exchange; NA: not applicable; MD: missing data; CI: confidence 
interval; SD: standard deviation; NMO: neuromyelitis optica; NMOSD: neuromyelitis optica spectrum disorder; AQP4-ab: aquapo­
rin-4 antibody. 
aMann–Whitney U test was performed to compare continuous data. 
bCategorical data were compared using exact chi-square test. 
cNMO fulfilling Wingerchuk’s criteria.10 
dAlemtuzumab, cyclosporine A, fingolimod, intravenous immunoglobulins, steroids intravenous, tocilizumab, natalizumab, myco­
phenolate mofetile, and methotrexate. 
eTo adjust for intraindividual dependencies we additionally applied generalized estimating equations (GEEs) with patient as statisti­
cal unit for analysis. Shown are median and interquartile range (IQR) or mean ± SD when normally distributed. 
http://msj.sagepub.com 5 
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Table 3. Comparison between female NMO/SD patients of fertile age and beyond fertile age at onset. 
Age between 15 and 
40 years (n = 42) 
Age >40 years 
(n = 51) (reference) 
p-value Odds ratio (95% CI) 
Time between onset and 
diagnosis (months) 
31 (±31) 22 (±21) 0.25a 
AQP4-ab-positive 38/42 (91%) 49/51 (96%) 0.27b 
Annualized relapse rate (clinical 
observation ⩾2 and <10 years) 
1.1 (±0.7) 1.0 (±0.6) 0.98a 
Disease classification 
NMOc 36/42 (86%) 31/51 (61%) 0.008b 
NMOSD 6/42 (14%) 20/51 (39%) 
Type of attack (n = 468 attacks in 93 patients) 
Optic neuritis (ON) 69/226 (31) 58/242 (24) 0.10d 0.803 (0.618–1.04) 
Myelitis 129/226 (57) 155/242 (64) 
ON + myelitis 19/226 (8) 28/242 (12) 
Others 9//226 (4) 1/242 (0.4) 
Remission overall (n = 468 attacks in 93 patients) 
Complete 57/226 (25) 29/242 (12) 0.003d 0.361 (0.185–0.705) 
Incomplete/no 136/226 (60) 189/242 (78) 
MD 33/226 (15) 24/242 (10) 
Remission HD-S (first pulse) (n = 338 attacks in 93 patients) 
Complete 32/155 (21) 19/183 (10) 0.005d 0.353 (0.172–0.728) 
Incomplete/no 108/155 (70) 156/183 (85) 
MD 15/155 (10) 9/183 (5) 
Remission TPE (first cycle) (n = 38 attacks in 15 patients) 
Complete 15/18 (83) 0/20 (0) NA No solution for GEE 
Incomplete/no 2/18 (11) 19/20 (95) 
MD 1/18 (6) 1/20 (5) 
Remission immunoadsorption (first cycle) (n = seven attacks in five patients) 
Complete 0/7 (0) 0/0 (0) NA 
Incomplete/no 7/7 (100) 0/0 (0) 
HD-S: high-dose intravenous steroids; TPE: therapeutic plasma exchange; NA: not applicable; MD: missing data; CI: confidence 
interval; SD: standard deviation; NMO: neuromyelitis optica; NMOSD: neuromyelitis optica spectrum disorder; AQP4-ab: aquapo­
rin-4 antibody. 
To ensure a similar duration of clinical observation in both groups, only women with an observation period of >2 and ⩽10 years 
were included in the analysis. 
aMann–Whitney U test was performed to compare continuous data. 
bCategorical data were compared using exact chi-square test. 
cNMO fulfilling Wingerchuk’s criteria.10 
dTo adjust for intraindividual dependencies, we additionally applied generalized estimating equations (GEEs) with patient as statisti­
cal unit for analysis. Shown are median and interquartile range (IQR) or mean ± SD when normally distributed. 
Many autoimmune diseases show a female predomi­
nance, for example, SLE and MS. As in our NMO/SD 
study, female preponderance is also marked during 
fertile age in SLE.16 Studies in pediatric MS showed a 
balanced sex ratio in children <11years17 and highest 
female-to-male ratios in patients between 12 and 
15 years,17,18 suggesting that hormonal changes dur­
ing puberty have an impact on MS onset; female-to­
male ratio declined with increasing age and showed a 
male excess in MS patients with disease onset after 
the 50th year of age.18 
Previous studies described a strong female predomi­
nance in pediatric NMO.2,19 In our cohort, the number 
of patients with pediatric onset was very low (n = 6). 
We cannot rule out that the female-to-male ratio of 
2:1 found in this age group is due to low patient num­
bers or to differences in ethnic background between 
studies. 
Diagnosis of NMO/SD was significantly delayed in 
women compared to men. Being misdiagnosed with 
MS was the main reason for this delay. Prior to the 
http://msj.sagepub.com 6 
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Table 4. Comparison between male NMO/SD patients between 15 and 40years and >40years of age. 
Age between 15 and 
40 years (n = 10) 
Age >40 years 
(n = 22) 
p-value Odds ratio (95% CI) 
Time between onset and 
diagnosis (months) 
37 (±56) 16 (±26) 0.41a 
AQP4-ab-positive 3 (30%) 14 (64%) 0.12b 
Annualized relapse rate (clinical 
observation >1 year) 
1.0 (0.7–1.5) 1.0 (0.7–1.8) 0.62a 
Disease classification 
NMOc 10 (100%) 18 (82%) 0.15b 
NMOSD 0 (0%) 4 (18%) 
Type of attack (n = 135 in 33 patients) 
Optic neuritis (ON) 14/51 17/84 0.71d 0.917 (0.582–1.45) 
Myelitis 32/51 59/84 
ON + myelitis 5/51 7/84 
Other 0/51 1/84 
Remission overall (n = 135 attacks in 33 patients) 
Complete 13/51 (25) 10/84 (12) 0.06d 0.371 (0.134–1.02) 
Incomplete/no 37/51 (73) 73/84 (87) 
MD 1/51 (2) 1/84 (1) 
Remission HD-S (first pulse) (n = 114 attacks in 32 patients) 
Complete 11/45 (24) 9/69 (13) 0.12d 0.417 (0.139–1.255) 
Incomplete/no 33/45 (73) 59/69 (86) 
MD 1/45 (2) 1/69 (1) 
Remission TPE (first cycle) (n = eight attacks in five patients) 
Complete 0/0 1/8 (13) NA 
Incomplete/no 0/0 7/8 (87) 
Remission immunoadsorption (first cycle) (n = one attack in one patient) 
Complete 1/1 (100) 0/0 (0) NA 
Incomplete/no 0/1 (0) 0/0 (0) 
HD-S: high-dose intravenous steroids; TPE: therapeutic plasma exchange; NA: not applicable; MD: missing data; CI: confidence 
interval; SD: standard deviation; NMO: neuromyelitis optica; NMOSD: neuromyelitis optica spectrum disorder; AQP4-ab: aquapo­
rin-4 antibody; GEE: generalized estimating equation. 
Shown are median and interquartile range (IQR) or mean ± SD when normally distributed. 
aExact Mann–Whitney test. 
bExact chi-square test. 
cNMO fulfilling Wingerchuk criteria.10 
dGEE analysis. 
availability of AQP4-ab testing, up to 42% of NMO 
patients were misdiagnosed as MS.4 The higher preva­
lence of MS compared to NMO and the fact that NMO 
was considered to be a form of MS might be the rea­
sons for this finding. We did not observe differences in 
ARR between male and female patients; therefore, fre­
quency of attacks does not serve as explanation for dif­
ferences in duration between onset and diagnosis. 
Given the severity of attacks in NMO/SD and the dif­
ferences in treatment response between NMO/SD and 
MS,20,21 an early correct diagnosis is essential.22 
Besides prevalence, clinical features in autoimmune 
diseases are known to be influenced by sex. In our 
cohort, AQP4-abs were more frequent in female 
patients. Other studies confirmed a female predomi­
nance among seropositive patients.4,5 Sex differences 
in antibody serum status are also known in other auto­
immune diseases. Of note, anti-SSA and anti-SSB 
were detected more often in women with SLE,23 
whereas anti-dsDNA were shown to be more preva­
lent among male patients.24 Thus, a female predomi­
nance is not necessarily found in antibody-mediated 
autoimmune diseases. The reasons for sex differences 
in the prevalence of autoreactive autoantibodies are 
not fully understood, but they might be of importance 
as NMO/SD possibly takes a more severe course in 
seropositive patients.4,25,26 
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Sex differences in predisposition and course of auto­
immune diseases are, first and foremost, assumed to 
be based on differences in immunocompetence and 
immune reactivity. Hormonal factors, for example, 
differences in circulating sex hormones or changes in 
hormone receptor expression are supposed to be 
involved in sex differences in autoimmune diseases.27 
Moreover, differences in major histocompatibility 
complex (MHC) risk alleles, in genetic imprinting, in 
the transcription of inflammation-related genes, and 
in the responsiveness to environmental factors, for 
example, infections, smoking, or sun exposure, have 
to be taken into consideration.28,29 Women are known 
to show significantly stronger immune responses to 
infections and vaccination.30 Immunological toler­
ance might be more strongly controlled by hormonal 
factors, especially before menopause and during 
pregnancy. 
We chose the cutoff of 40years to compare female 
patients during and beyond fertile age. In general, 
menopause starts at an age of 50 years and is charac­
terized by the last menstrual period. However, a 
decline in fertility already starts up to 10years before, 
as pregnancy rates are continuously decreasing after 
the age of 40 years.12 The decline in reproductive 
function of the ovaries is accompanied by various 
hormonal changes, for example, of growth hormone, 
follicle-stimulating hormone, and estradiol,31 which 
might have an influence on autoimmunity.32,33 
In women, response to attack treatment was age 
related. Complete remission and a better response to 
treatment with HD-S were found more frequently at 
an age <40years. We did not observe the same age 
dependency in male patients, which might primarily 
be due to the small sample size of the male group. In 
other diseases, for example, in MS, age seems to 
influence attack severity and recovery.34 Some studies 
described an overall better recovery from MS attacks 
in young-onset patients,18 whereas others found no 
differences or even reverse results.35 However, in 
these studies, the influence of different treatment regi­
mens was not explicitly considered. 
The retrospective design of our study is a potential 
limitation. However, NMO/SD is a very rare disorder 
and was recognized as a disease entity distinct from 
MS only a few years ago. Thus, to date, only retro­
spective analyses allow to investigate epidemiologic 
and clinical features in large cohorts of NMO/SD 
patients. Another limitation is the small sample size of 
the male and pediatric subgroups in our cohort. 
Although the NEMOS cohort is one of the largest 
NMO/SD cohorts published to date, our study 
includes only 34 male patients and six children 
<15years. The cutoffs for fertile age used in this study 
are necessarily arbitrary (15–40 years), as the begin­
ning of menstrual irregularities was not systemati­
cally recorded in our study. Desirable for further 
studies would be the use of time-dependent covariates 
(exact date of last and first menses) in the statistical 
analysis. Finally, no structured pregnancy data were 
recorded in our study, which is another limitation. 
As a major strength and different from previous stud­
ies, our data are derived from a very large cohort from 
a country where almost everybody has access to the 
healthcare system, reducing a bias toward more 
severely affected patients as well as potential genetic 
confounders. 
Given the results from this retrospective, exploratory 
study, larger prospective studies are now warranted. A 
novelty of our study was to include (although arbi­
trary) cutoffs for reproductive age; this should also be 
considered in future studies. Such future studies 
should investigate potential confounders related to 
long-term treatment in more detail, should include 
more male patients and the exact dates of menarche 
and menopause to determine the real “fertile age.” 
Our study provides a strong rationale for future pro­
spective studies exploring the effect of sex as well for 
the inclusion of respective subgroup analyses in future 
treatment trials in NMO/SD. 
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